Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Free Cash Flow: 2011-2025

Historic Free Cash Flow for Adma Biologics (ADMA) over the last 11 years, with Sep 2025 value amounting to -$1.1 million.

  • Adma Biologics' Free Cash Flow fell 104.48% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.7 million, marking a year-over-year decrease of 48.70%. This contributed to the annual value of $110.4 million for FY2024, which is 2641.28% up from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' Free Cash Flow is -$1.1 million, which was down 105.74% from $18.7 million recorded in Q2 2025.
  • Adma Biologics' Free Cash Flow's 5-year high stood at $47.5 million during Q4 2024, with a 5-year trough of -$37.1 million in Q4 2021.
  • In the last 3 years, Adma Biologics' Free Cash Flow had a median value of $11.2 million in 2023 and averaged $9.8 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first skyrocketed by 728.77% in 2024, then slumped by 433.98% in 2025.
  • Quarterly analysis of 5 years shows Adma Biologics' Free Cash Flow stood at -$37.1 million in 2021, then spiked by 70.04% to -$11.1 million in 2022, then spiked by 247.38% to $16.4 million in 2023, then skyrocketed by 189.38% to $47.5 million in 2024, then slumped by 104.48% to -$1.1 million in 2025.
  • Its Free Cash Flow stands at -$1.1 million for Q3 2025, versus $18.7 million for Q2 2025 and -$24.4 million for Q1 2025.